Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: J Allergy Clin Immunol. 2016 Jun 11;139(2):462–471.e14. doi: 10.1016/j.jaci.2016.04.037

Fig 2.

Fig 2

IL-13Rα2 is not required for IL-17A-mediated enhancement of IL-13-induced pathology. AHR in WT or IL-13Rα2−/− mice treated with IL-13 or IL-17A i.t. (A), total cell counts from BAL fluid of cytokine treated animals (B), frequency of macrophages, lymphocytes, neutrophils, and eosinophils in the BAL fluid (C,D), total lung expression of IL-13 (E) and IL-17A (F) induced transcripts following cytokine treatment. # and ## indicate P<0.05 and <0.01 vs PBS. + and +++ indicate P<0.05 and <0.001 vs IL-13 (A,B) or IL-17A (F). Mean + SEM of n=5-11 mice per group (pooled over 3 independent experiments) are shown.